Alan McDougall

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

Bob W. van Oosten, Mitchell K.P. Lai, Suzanne Hodgkinson et al. · Neurology · 1997 · 268 citations

Life Sciences, Immunology, Neurology +15

Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial

Peter Mitchell, Bernard Yan, Leonid Churilov et al. · The Lancet · 2022 · 227 citations · Full text

Medicine, Cardiology, Surgery +14

Kufs Disease, the Major Adult Form of Neuronal Ceroid Lipofuscinosis, Caused by Mutations in CLN6

Todor Arsov, Katherine R. Smith, John A. Damiano et al. · The American Journal of Human Genetics · 2011 · 162 citations · Full text

Medicine, Molecular Genetics, Neuroscience +4

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Graeme J. Hankey, Maree L. Hackett, Osvaldo P. Almeida et al. · The Lancet Neurology · 2020 · 145 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Autonomic nervous system function in multiple sclerosis

Alan McDougall, J. G. McLeod · Journal of the Neurological Sciences · 2003 · 96 citations

Life Sciences, Neurology, Neuroscience +14